In patients with recurrent/metastatic cervical cancer, the PD-1 inhibitor balstilimab monotherapy or combined with the CTLA-4 inhibitor zalifrelimab demonstrated promising objective response rates no matter the patients PD-L1 status, plus a tolerable safety profile, according to data from 2 independent phase 2 trials presented during the 2020 ESMO Virtual Congress.
Frontline nivolumab in combination with cabozantinib demonstrated a 49% reduction in the risk of disease progression or death as treatment of patients with advanced renal cell carcinoma.
Avelumab in combination with best supportive care as frontline maintenance in patients with advanced or metastatic urothelial carcinoma who had not progressed on first-line platinum-based chemotherapy led to improvements in both progression-free and overall survival.
In a phase 2 clinical trial, promising clinical activity was observed with cemiplimab in patients with locally advanced basal cell carcinoma who progress on or are intolerant to hedgehog inhibitors, regardless of PD-L1 expression, according to findings presented at the 2020 ESMO Virtual Congress.